JDD Buzz Series | The Burden of Melasma
A study in the August Journal of Drugs in Dermatology addressed the burden of melasma – the populations most prone to melasma and the comorbidities associated with it. According to the study’s authors, a deeper understanding of the associations of race, ethnicity and comorbidities can help dermatologists determine which patients are at risk of developing melasma and as well as potential new pa …
A study in the August Journal of Drugs in Dermatology addressed the burden of melasma – the populations most prone to melasma and the comorbidities associated with it. According to the study’s authors, a deeper understanding of the associations of race, ethnicity and comorbidities can help dermatologists determine which patients are at risk of developing melasma and as well as potential new pa … 
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to … 
TikTok is a source of beauty and skin health information for the masses. Yet much of the content is not produced by board-certified dermatologists or even other healthcare professionals. So who’s creating TikTok content about sun protection and skin cancer? Does any of this content address skin of color? Those are the questions a new cross-sectional analysis published in the July Journal of Drug … 
In the August edition of the Journal of Drugs in Dermatology (JDD), we turn our focus to psoriasis, one of the most challenging and impactful dermatological conditions. This month’s Editor's Picks showcase a series of in-depth studies and expert discussions that explore the latest advancements in psoriasis treatment, real-world effectiveness, and the broader implications of the disease … 
Our latest blog post explores the study "Racial and Ethnic Diversity in Vitiligo Clinical Trials: A Retrospective Cross-Sectional Study Assessing Demographic Reporting of Participants" published in the Journal of Drugs in Dermatology by Holla et al.
Key Findings:
Significant gaps in demographic reporting.
Underrepresentation of non-White participants.
The need for inclusive res … 